BUZZ-Emergent climbs as FDA approves smallpox vaccine for high-risk mpox cases

Updates

** Shares of Emergent BioSolutions EBS.N up ~3.5% at $9.27

** U.S. Food and Drug Administration (FDA) has approved expanded use of Emergent's ACAM2000 smallpox vaccine to include people at high risk for mpox infection

** FDA's approval follows Emergent's application for an Emergency Use Listing of ACAM2000 vaccine with the World Health Organization

** ACAM2000 has more known side effects and risks than Danish biotech Bavarian Nordic A/S's BAVA.CO Jynneos vaccine, which is approved in the United States for both smallpox and mpox

** Earlier this month, WHO declared mpox a global public health emergency for the second time in two years

** EBS has quadrupled in value this year despite losing ~30% of its value this month

(Reporting by Medha Singh and Christy Santhosh in Bengaluru)

((medha.singh@thomsonreuters.com))